PCSK9
Proprotein convertase subtilisin/kexin type 9
The protein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene located on human chromosome 1. It is the ninth member of the protein convertase family, a group of enzymes that can activate homologous genes found in many species[1]. PCSK9 is a liver-synthesized protease that plays a major role in regulating the levels of low-density lipoprotein receptors (LDLR) on the surface of liver cells and can inhibit the LDLR recycling pathway. PCSK9 binds to LDLR on the surface of liver cells, escorts LDLR to lysosomes for degradation, and prevents LDLR from recirculating to the cell membrane, effectively increasing the level of circulating LDL. Therefore, inhibiting the activity of the PCSK9 protease can down-regulate circulating LDL levels. PCSK9 is closely associated with various cardiovascular diseases, especially hypercholesterolemia and atherosclerosis[2].
All Product Categories
-
PCSK9 Related Products (96)
Related Products (96)
-
PCSK9-IN-30
0 ImagesCat. No.: HY-161940PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC50 = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases.
-
PF-06815345
0 ImagesCat. No.: HY-112598CAS No.: 1900686-46-5
-
Bezeparsen sodium
0 ImagesCat. No.: HY-147252ABezeparsen sodium is a PCSK9 synthesis inhibitor.
-
Tafolecimab
0 ImagesCat. No.: HY-P99552CAS No.: 2225109-03-3Synonyms: IBI-306Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia.
-
Ticalicibart
0 ImagesTicalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research.
-
PCSK9-IN-29
0 ImagesPCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity.
-
CVI-LM001
0 ImagesCat. No.: HY-148626CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy.
-
Bezeparsen
0 ImagesCat. No.: HY-147252CAS No.: 2639640-84-7Bezeparsen is a PCSK9 synthesis inhibitor.
-
Anti-PCSK9 Antibody
0 ImagesCat. No.: HY-P990485Purity: 98.39%Anti-PCSK9 Antibody is a human antibody expressed in CHO, targeting PCSK9. Anti-PCSK9 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
-
PCSK9 modulator-2
0 ImagesCat. No.: HY-128334CAS No.: 2365416-53-9PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC50 value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia.
-
PCSK9-IN-16
0 ImagesCat. No.: HY-153452CAS No.: 2455424-51-6
-
PCSK9-IN-34
0 ImagesCat. No.: HY-179106CAS No.: 3035306-81-8PCSK9-IN-34 is a small molecule PCSK9 inhibitor. PCSK9-IN-34 can be used for research on cardiovascular conditions.
-
SPC4061
0 ImagesCat. No.: HY-148689CAS No.: 1018108-22-9
-
PCSK9 modulator-3
0 ImagesCat. No.: HY-146084CAS No.: 2476490-18-1PCSK9 modulator-3 (Compound 13) is a potent modulator of PCSK9 with an EC50 value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia.
-
SPC4061 sodium scrambled negative control
0 ImagesCat. No.: HY-148689CSPC4061 sodium scrambled negative control is the sequence scrambled negative control of SPC4061 sodium.
-
(R,R)-PCSK9 degrader 1
0 ImagesCat. No.: HY-130245ACAS No.: 2216703-12-5(R,R)-PCSK9 degrader 1 is the isomer of PCSK9 degrader 1 (HY-130245). PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a Ki of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor.
